The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. Here's why this $150 billion pharmaceutical powerhouse deserves a ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Investors may prefer to hunt for strong dividends right now, as opposed to playing in the volatile stock market. While not as ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for drugmakers.

AMGN stock opened at $271.90 on Tuesday. The firm’s 50-day simple moving average is $287.76 and its 200 day simple moving average is $287.05. Amgen has a fifty-two week low of $253.30 and a ...

Sanofi plans to buy Vig­il Neu­ro­science, a drug­mak­er ad­vanc­ing TREM2 ag­o­nism pro­grams that de­rive from Am­gen.

A seminal decision concerning second medical use patents and questions over confidentiality were among the top talking points ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.